" efflux were investigated in erythrocytes of 41 patients with cystic fibrosis and 26 controls. Na + -independent Mg 2 " 1 " efflux was unchanged in cystic fibrosis, but a significantly increased activity of Na+/Mg 2+ antiport was detected (control: 0.16 ± 0.02, cystic fibrosis: 0.39 ± 0.06, Mg 2+ efflux, mmol/30min X l cells, mean ± SEM, p < 0.01). An increased activity of Na + /Mg 2+ antiport was only found in patients with severe clinical Symptoms. There was no correlation of the increased Na + /Mg 2+ antiport to the dF508 genotype. In a patient with increased Na"*"/Mg 
Introduction
In patients with cystic fibrosis the cystic fibrosis transmembrane conductance regulator is mutated. A deletion of phenylalanine at codon 508 is found in about 70% of Caucasian cystic fibrosis patients; hundreds of different mutations of the cystic fibrosis gene have been described in the remaining 30% of patients (1) . Besides the defect in eAMP-dependent Chloride transport, other defects have been observed 1 in cystic fibrosis, such äs increased Na + äbsorption across airway epithelia, reduced mucin .secretion from salivary gländs and increased sulphatation of glycoconjugates secreted by airway epithelia (äs reviewed in 1. c. (2)). It has been suggested that these defects are secondary to the reduced Cl~ conductance, ör that they may represent additional regulatory functions of cystic fibrosis transmembrane conductance regulator. The latter not only functions äs a Cl" channel but also seeins to iiifluence the activity of other transport proteins by leading to a cystic fibrosis transmembrane conductance regulator-associated protein kinase A activation, for example, of the outwardly rectifying Chloride channel (3). In cystic fibrosis, re- " concentration in sweat, and that it is not coupled to the dF508 genotype of cystic fibrosis.
Materials and Methods

Patients
Cystic fibrosis patients (n = 41; 23 female, 18 male) and 26 age matched controls (11 female, 15 male) not affected with cystic fibrosis were included in the study. Age (in years), mean ± SD: patients 19.4 ± 10.3, controls 21.4 ± 14.4. All patients had chronic Pseudomonas aeroginosa infection of the lungs, suffered from pancreas insufficiency, and had not been treated with amiloride. The patients were routinely genotyped. Patients were divided into three groups based on the severity of their clinical Symptoms, accofding to the Shwachman score without X-ray examination (8): mild (CF1) > 55, medium (CF2) 55-41, severe (CF3) < 41 points.
Sweat fest
Sweat tests were performed on the forearm with pilocarpine iontophoresis with a Webster sweat inducer System (Wescor, Logan, Utah, USA). For measurement of the Mg 2+ concentration in sweat 10 μΐ samples were diluted with l ml 100 g/l trichloroacetic acid/ l .75 g/l LaCla and Mg 2 " 1 " was measured by atomic absorption spectrophotometry (AAS, Philips SP9).
Mg 2 + efflux
Heparinized blood was taken from controls and cystic fibrosis patients. Blood was centrifuged at 1000g for 10 min. The erythrocytes were taken for the measurement of Mg 2 " 4 " efflux, s already described (4) . Briefly, the cells were loaded with Mg "-free N Cl medium (Substitution of KC1 in KC1 medium by 140 mmol/1 NaCl) or Mg 2+ -free choline Chloride medium (Substitution of KC1 in KC1 medium by 140 mmol/1 choline Chloride). At the beginning of reincubation and after 30 min, 0.5 ml aliquots of the cell suspensions were centrifuged for l min at 10000#. Aliquots (100 μΐ) of the supernatants were diluted with l ml 100 g/l trichloroacetic acid/1.75 g/l LaCl 3 , and Mg independent Mg 2+ efflux at physiological extracellular Cl concentration) from Mg 2 "*" efflux in Na"*" medium. " antiport, however, is more than doubled in cystic fibrosis patients. The elevated mean is due to high values in some patients, whereas other patients had normal antiport rates. By dividing the patients into three groups according to the severity of their disease, it was obvious that particularly patients with severe cliriical Symptoms (CF3) showed an increased Na^/Mg 2 " 1 " antiport capacity, whereas none of the other patients (CF1 or CF2) showed ahy change in transport capacity (tab. 2, fig. 1 ). In all patients with increased Na~*7Mg 2+ antiport, this transport was inhibited by l mmol/1 amiloride ( fig. 1 ), which also inhibited Na^/Mg 2 " 1 " antiport in controls and cystic fibrosis patients with normal transport rates. Figure 2 shows the Na + /Mg 2+ antiport rates of patients with the homozygous dF508 mutation, classified according to the Shwachman score. The increased Na^/Mg -loaded erythrocytes from cystic fibrosis patients with the homozygous dF508 mutation subdivided into groups according to the severity of their clinical Symptoms.
Results
patients (dF508 heterozygous with additional mutations, or homozygous for mutations of the eystic fibrosis gene öther thän dF508) no correlatiqn between genotype and Na + /Mg 2+ antiport could be detected.
One patient with increased Na + /Mg 2 +.ajitiport (Mg " antiport (tab. 3), i.e. only the patients with the Jiighest severity score (CF3) showed significantly increased sweat Mg 2+ concentrations.
Discussion
Intracellular Mg 2+ is needed for many physiological and metabolic fimctions, i. e. activation of enzymes, charge reduction of negatively loaded substances like DNA or RNA and regulation of ion channels (9) . To fulfil these tasks, the intracellular concentration of free Mg " exchange) (review in 1. c. (10)). As we report here, in human erythrocytes it is specifically increased in a sub-population of cystic fibrosis patients with a severe clinical condition.
The increased Na + /Mg 2H~ antiport in cystic fibrosis is not coupled to the dF508 genotype or any other known mutation of the cystic fibrosis gene, äs patients with homozygous dF508 mutations display normal äs well äs increased antiport. It is likely that the increased Na + / Mg 24 " antiport is caused by an äs yet unknown effect of the disease that only develops in a subgroup of severely affected patients. In accprdance with this result, the clinical severity of cystic fibrosis was also not correlated with the genotype (1). This also agrees with the findings after lung transplantation. Transplantation of the lung induced normalisation of Na^/Mg supply would then be beneficial to these cystic fibrosis patients.
